Precigen, Inc.

Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology. The company focuses on targeting diseases in immuno-oncology, autoimmune disorders, and infectious diseases. Its therapeutic platforms include the AdenoVerse platform, which uses a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigens, and the UltraCAR-T platform, which provides chimeric antigen receptor T cell therapies for cancer patients. Key pipeline programs include PRGN-3005 for advanced ovarian, fallopian tube, or primary peritoneal cancer (Phase 1/1b), PRGN-3006 for relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes (Phase 1b), and PRGN-3007 for advanced receptor tyrosine kinase-like orphan receptor 1-positive hematologic and solid tumors (Phase 1/1b). Additionally, the AdenoVerse platform includes PRGN-2009 for HPV+ solid tumors (Phase 2) and PRGN-2012 for recurrent respiratory papillomatosis (Phase 1/2). The company also developed UltraPorator, a proprietary electroporation device.

Precigen, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol PGEN. The stock trades in United States Dollars (USD). As a US-based company listed on a major US exchange, its financial reporting and trading are conducted in USD, making it accessible to investors through standard US brokerage accounts.

Precigen, Inc. operates in the Healthcare sector and specifically within the Biotechnology industry. As a biotechnology company, it focuses on developing innovative therapies using gene and cell engineering technologies. Its work involves precision gene delivery and cell therapy platforms to address serious medical conditions such as cancers, autoimmune disorders, and infectious diseases. The company's clinical-stage pipeline reflects its commitment to advancing novel treatments through rigorous research and development.

Precigen, Inc. is headquartered in Germantown, Maryland, United States. The company was founded in 1998 and was formerly known as Intrexon Corporation before rebranding to Precigen in February 2020. Its operations are primarily based in the US, and it serves global markets through its research and clinical development activities. The company's focus on precision gene and cell therapies positions it within the broader US biotechnology landscape.

Precigen's key therapeutic platforms are the AdenoVerse platform and the UltraCAR-T platform. The AdenoVerse platform uses a library of proprietary adenovectors for gene delivery, enabling the development of immunotherapies and vaccines. Key programs include PRGN-2009 (Phase 2 for HPV+ solid tumors) and PRGN-2012 (Phase 1/2 for recurrent respiratory papillomatosis). The UltraCAR-T platform provides chimeric antigen receptor T cell therapies, with programs such as PRGN-3005 (Phase 1/1b for advanced ovarian, fallopian tube, or primary peritoneal cancer), PRGN-3006 (Phase 1b for relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes), and PRGN-3007 (Phase 1/1b for advanced receptor tyrosine kinase-like orphan receptor 1-positive hematologic and solid tumors). Additionally, the company developed UltraPorator, a proprietary electroporation device used in its therapies.